Global CRISPR and CRISPR-Associated (Cas) Genes Market Analysis and Forecast 2024-2030
Summary
This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.
Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of 'spacer DNA' from previous exposures to a bacteriophage virus or plasmid.
The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.
Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.
By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.
According to APO Research, The global CRISPR and CRISPR-Associated (Cas) Genes market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of CRISPR and CRISPR-Associated (Cas) Genes include Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics, Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich and Precision Biosciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for CRISPR and CRISPR-Associated (Cas) Genes, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of CRISPR and CRISPR-Associated (Cas) Genes, also provides the revenue of main regions and countries. Of the upcoming market potential for CRISPR and CRISPR-Associated (Cas) Genes, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the CRISPR and CRISPR-Associated (Cas) Genes revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global CRISPR and CRISPR-Associated (Cas) Genes market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for CRISPR and CRISPR-Associated (Cas) Genes revenue, projected growth trends, production technology, application and end-user industry.
CRISPR and CRISPR-Associated (Cas) Genes segment by Company
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CRISPR and CRISPR-Associated (Cas) Genes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CRISPR and CRISPR-Associated (Cas) Genes and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CRISPR and CRISPR-Associated (Cas) Genes.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of CRISPR and CRISPR-Associated (Cas) Genes in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of CRISPR and CRISPR-Associated (Cas) Genes company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CRISPR and CRISPR-Associated (Cas) Genes revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.
Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of 'spacer DNA' from previous exposures to a bacteriophage virus or plasmid.
The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.
Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.
By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.
According to APO Research, The global CRISPR and CRISPR-Associated (Cas) Genes market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of CRISPR and CRISPR-Associated (Cas) Genes include Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics, Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich and Precision Biosciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for CRISPR and CRISPR-Associated (Cas) Genes, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of CRISPR and CRISPR-Associated (Cas) Genes, also provides the revenue of main regions and countries. Of the upcoming market potential for CRISPR and CRISPR-Associated (Cas) Genes, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the CRISPR and CRISPR-Associated (Cas) Genes revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global CRISPR and CRISPR-Associated (Cas) Genes market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for CRISPR and CRISPR-Associated (Cas) Genes revenue, projected growth trends, production technology, application and end-user industry.
CRISPR and CRISPR-Associated (Cas) Genes segment by Company
- Thermo Fisher Scientific
- Editas Medicine
- Caribou Biosciences
- CRISPR therapeutics
- Intellia therapeutics, Inc.
- Cellectis
- Horizon Discovery Plc
- Sigma Aldrich
- Precision Biosciences
- Genscript
- Sangamo Biosciences Inc.
- Lonza Group Limited
- Integrated DNA Technologies
- New England Biolabs
- Origene Technologies
- Genome Editing
- Genetic engineering
- gRNA Database/Gene Librar
- CRISPR Plasmid
- Human Stem Cells
- Genetically Modified Organisms/Crops
- Cell Line Engineering
- Biotechnology Companies
- Pharmaceutical Companies
- Academic Institutes
- Research and Development Institutes
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CRISPR and CRISPR-Associated (Cas) Genes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CRISPR and CRISPR-Associated (Cas) Genes and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CRISPR and CRISPR-Associated (Cas) Genes.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of CRISPR and CRISPR-Associated (Cas) Genes in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of CRISPR and CRISPR-Associated (Cas) Genes company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CRISPR and CRISPR-Associated (Cas) Genes revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 CRISPR and CRISPR-Associated (Cas) Genes Market by Type
1.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Genome Editing
1.2.3 Genetic engineering
1.2.4 gRNA Database/Gene Librar
1.2.5 CRISPR Plasmid
1.2.6 Human Stem Cells
1.2.7 Genetically Modified Organisms/Crops
1.2.8 Cell Line Engineering
1.3 CRISPR and CRISPR-Associated (Cas) Genes Market by Application
1.3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Biotechnology Companies
1.3.3 Pharmaceutical Companies
1.3.4 Academic Institutes
1.3.5 Research and Development Institutes
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET DYNAMICS
2.1 CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
2.2 CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers
2.3 CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges
2.4 CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Perspective (2019-2030)
3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Growth Trends by Region
3.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2019-2024)
3.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Players
4.1.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Players (2019-2024)
4.1.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Players (2019-2024)
4.1.3 Global CRISPR and CRISPR-Associated (Cas) Genes Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Headquarters & Area Served
4.4 Global CRISPR and CRISPR-Associated (Cas) Genes Players, Product Type & Application
4.5 Global CRISPR and CRISPR-Associated (Cas) Genes Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market CR5 and HHI
4.6.2 Global Top 5 and 10 CRISPR and CRISPR-Associated (Cas) Genes Players Market Share by Revenue in 2023
4.6.3 2023 CRISPR and CRISPR-Associated (Cas) Genes Tier 1, Tier 2, and Tier
5 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET SIZE BY TYPE
5.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2030)
5.3 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2019-2030)
6 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET SIZE BY APPLICATION
6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2030)
6.3 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Thermo Fisher Scientific
7.1.1 Thermo Fisher Scientific Comapny Information
7.1.2 Thermo Fisher Scientific Business Overview
7.1.3 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.1.4 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.1.5 Thermo Fisher Scientific Recent Developments
7.2 Editas Medicine
7.2.1 Editas Medicine Comapny Information
7.2.2 Editas Medicine Business Overview
7.2.3 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.2.4 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.2.5 Editas Medicine Recent Developments
7.3 Caribou Biosciences
7.3.1 Caribou Biosciences Comapny Information
7.3.2 Caribou Biosciences Business Overview
7.3.3 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.3.4 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.3.5 Caribou Biosciences Recent Developments
7.4 CRISPR therapeutics
7.4.1 CRISPR therapeutics Comapny Information
7.4.2 CRISPR therapeutics Business Overview
7.4.3 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.4.4 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.4.5 CRISPR therapeutics Recent Developments
7.5 Intellia therapeutics, Inc.
7.5.1 Intellia therapeutics, Inc. Comapny Information
7.5.2 Intellia therapeutics, Inc. Business Overview
7.5.3 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.5.4 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.5.5 Intellia therapeutics, Inc. Recent Developments
7.6 Cellectis
7.6.1 Cellectis Comapny Information
7.6.2 Cellectis Business Overview
7.6.3 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.6.4 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.6.5 Cellectis Recent Developments
7.7 Horizon Discovery Plc
7.7.1 Horizon Discovery Plc Comapny Information
7.7.2 Horizon Discovery Plc Business Overview
7.7.3 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.7.4 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.7.5 Horizon Discovery Plc Recent Developments
7.8 Sigma Aldrich
7.8.1 Sigma Aldrich Comapny Information
7.8.2 Sigma Aldrich Business Overview
7.8.3 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.8.4 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.8.5 Sigma Aldrich Recent Developments
7.9 Precision Biosciences
7.9.1 Precision Biosciences Comapny Information
7.9.2 Precision Biosciences Business Overview
7.9.3 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.9.4 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.9.5 Precision Biosciences Recent Developments
7.10 Genscript
7.10.1 Genscript Comapny Information
7.10.2 Genscript Business Overview
7.10.3 Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.10.4 Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.10.5 Genscript Recent Developments
7.11 Sangamo Biosciences Inc.
7.11.1 Sangamo Biosciences Inc. Comapny Information
7.11.2 Sangamo Biosciences Inc. Business Overview
7.11.3 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.11.4 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.11.5 Sangamo Biosciences Inc. Recent Developments
7.12 Lonza Group Limited
7.12.1 Lonza Group Limited Comapny Information
7.12.2 Lonza Group Limited Business Overview
7.12.3 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.12.4 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.12.5 Lonza Group Limited Recent Developments
7.13 Integrated DNA Technologies
7.13.1 Integrated DNA Technologies Comapny Information
7.13.2 Integrated DNA Technologies Business Overview
7.13.3 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.13.4 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.13.5 Integrated DNA Technologies Recent Developments
7.14 New England Biolabs
7.14.1 New England Biolabs Comapny Information
7.14.2 New England Biolabs Business Overview
7.14.3 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.14.4 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.14.5 New England Biolabs Recent Developments
7.15 Origene Technologies
7.15.1 Origene Technologies Comapny Information
7.15.2 Origene Technologies Business Overview
7.15.3 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.15.4 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.15.5 Origene Technologies Recent Developments
8 NORTH AMERICA
8.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue (2019-2030)
8.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2030)
8.2.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024)
8.2.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030)
8.3 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
8.4 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2030)
8.4.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024)
8.4.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030)
8.5 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
8.6 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
8.6.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024)
8.6.3 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue (2019-2030)
9.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2030)
9.2.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024)
9.2.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030)
9.3 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
9.4 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2030)
9.4.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024)
9.4.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030)
9.5 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
9.6 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
9.6.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024)
9.6.3 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China CRISPR and CRISPR-Associated (Cas) Genes Revenue (2019-2030)
10.2 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2030)
10.2.1 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024)
10.2.2 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030)
10.3 China CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
10.4 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2030)
10.4.1 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024)
10.4.2 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030)
10.5 China CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue (2019-2030)
11.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2030)
11.2.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024)
11.2.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030)
11.3 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
11.4 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2030)
11.4.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024)
11.4.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030)
11.5 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
11.6 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
11.6.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024)
11.6.3 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue (2019-2030)
12.2 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2030)
12.2.1 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024)
12.2.2 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030)
12.3 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
12.4 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2030)
12.4.1 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024)
12.4.2 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030)
12.5 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
12.6 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
12.6.1 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024)
12.6.3 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 CRISPR and CRISPR-Associated (Cas) Genes Market by Type
1.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Genome Editing
1.2.3 Genetic engineering
1.2.4 gRNA Database/Gene Librar
1.2.5 CRISPR Plasmid
1.2.6 Human Stem Cells
1.2.7 Genetically Modified Organisms/Crops
1.2.8 Cell Line Engineering
1.3 CRISPR and CRISPR-Associated (Cas) Genes Market by Application
1.3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Biotechnology Companies
1.3.3 Pharmaceutical Companies
1.3.4 Academic Institutes
1.3.5 Research and Development Institutes
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET DYNAMICS
2.1 CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
2.2 CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers
2.3 CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges
2.4 CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Perspective (2019-2030)
3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Growth Trends by Region
3.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2019-2024)
3.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Players
4.1.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Players (2019-2024)
4.1.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Players (2019-2024)
4.1.3 Global CRISPR and CRISPR-Associated (Cas) Genes Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Headquarters & Area Served
4.4 Global CRISPR and CRISPR-Associated (Cas) Genes Players, Product Type & Application
4.5 Global CRISPR and CRISPR-Associated (Cas) Genes Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market CR5 and HHI
4.6.2 Global Top 5 and 10 CRISPR and CRISPR-Associated (Cas) Genes Players Market Share by Revenue in 2023
4.6.3 2023 CRISPR and CRISPR-Associated (Cas) Genes Tier 1, Tier 2, and Tier
5 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET SIZE BY TYPE
5.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2030)
5.3 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2019-2030)
6 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET SIZE BY APPLICATION
6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2030)
6.3 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Thermo Fisher Scientific
7.1.1 Thermo Fisher Scientific Comapny Information
7.1.2 Thermo Fisher Scientific Business Overview
7.1.3 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.1.4 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.1.5 Thermo Fisher Scientific Recent Developments
7.2 Editas Medicine
7.2.1 Editas Medicine Comapny Information
7.2.2 Editas Medicine Business Overview
7.2.3 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.2.4 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.2.5 Editas Medicine Recent Developments
7.3 Caribou Biosciences
7.3.1 Caribou Biosciences Comapny Information
7.3.2 Caribou Biosciences Business Overview
7.3.3 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.3.4 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.3.5 Caribou Biosciences Recent Developments
7.4 CRISPR therapeutics
7.4.1 CRISPR therapeutics Comapny Information
7.4.2 CRISPR therapeutics Business Overview
7.4.3 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.4.4 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.4.5 CRISPR therapeutics Recent Developments
7.5 Intellia therapeutics, Inc.
7.5.1 Intellia therapeutics, Inc. Comapny Information
7.5.2 Intellia therapeutics, Inc. Business Overview
7.5.3 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.5.4 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.5.5 Intellia therapeutics, Inc. Recent Developments
7.6 Cellectis
7.6.1 Cellectis Comapny Information
7.6.2 Cellectis Business Overview
7.6.3 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.6.4 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.6.5 Cellectis Recent Developments
7.7 Horizon Discovery Plc
7.7.1 Horizon Discovery Plc Comapny Information
7.7.2 Horizon Discovery Plc Business Overview
7.7.3 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.7.4 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.7.5 Horizon Discovery Plc Recent Developments
7.8 Sigma Aldrich
7.8.1 Sigma Aldrich Comapny Information
7.8.2 Sigma Aldrich Business Overview
7.8.3 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.8.4 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.8.5 Sigma Aldrich Recent Developments
7.9 Precision Biosciences
7.9.1 Precision Biosciences Comapny Information
7.9.2 Precision Biosciences Business Overview
7.9.3 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.9.4 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.9.5 Precision Biosciences Recent Developments
7.10 Genscript
7.10.1 Genscript Comapny Information
7.10.2 Genscript Business Overview
7.10.3 Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.10.4 Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.10.5 Genscript Recent Developments
7.11 Sangamo Biosciences Inc.
7.11.1 Sangamo Biosciences Inc. Comapny Information
7.11.2 Sangamo Biosciences Inc. Business Overview
7.11.3 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.11.4 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.11.5 Sangamo Biosciences Inc. Recent Developments
7.12 Lonza Group Limited
7.12.1 Lonza Group Limited Comapny Information
7.12.2 Lonza Group Limited Business Overview
7.12.3 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.12.4 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.12.5 Lonza Group Limited Recent Developments
7.13 Integrated DNA Technologies
7.13.1 Integrated DNA Technologies Comapny Information
7.13.2 Integrated DNA Technologies Business Overview
7.13.3 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.13.4 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.13.5 Integrated DNA Technologies Recent Developments
7.14 New England Biolabs
7.14.1 New England Biolabs Comapny Information
7.14.2 New England Biolabs Business Overview
7.14.3 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.14.4 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.14.5 New England Biolabs Recent Developments
7.15 Origene Technologies
7.15.1 Origene Technologies Comapny Information
7.15.2 Origene Technologies Business Overview
7.15.3 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
7.15.4 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
7.15.5 Origene Technologies Recent Developments
8 NORTH AMERICA
8.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue (2019-2030)
8.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2030)
8.2.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024)
8.2.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030)
8.3 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
8.4 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2030)
8.4.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024)
8.4.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030)
8.5 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
8.6 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
8.6.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024)
8.6.3 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue (2019-2030)
9.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2030)
9.2.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024)
9.2.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030)
9.3 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
9.4 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2030)
9.4.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024)
9.4.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030)
9.5 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
9.6 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
9.6.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024)
9.6.3 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China CRISPR and CRISPR-Associated (Cas) Genes Revenue (2019-2030)
10.2 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2030)
10.2.1 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024)
10.2.2 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030)
10.3 China CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
10.4 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2030)
10.4.1 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024)
10.4.2 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030)
10.5 China CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue (2019-2030)
11.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2030)
11.2.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024)
11.2.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030)
11.3 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
11.4 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2030)
11.4.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024)
11.4.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030)
11.5 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
11.6 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
11.6.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024)
11.6.3 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue (2019-2030)
12.2 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2030)
12.2.1 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024)
12.2.2 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030)
12.3 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
12.4 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2030)
12.4.1 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024)
12.4.2 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030)
12.5 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
12.6 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
12.6.1 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024)
12.6.3 MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
LIST OF TABLES
Table 1. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Genome Editing Major Manufacturers
Table 2. Genetic engineering Major Manufacturers
Table 3. gRNA Database/Gene Librar Major Manufacturers
Table 4. CRISPR Plasmid Major Manufacturers
Table 5. Human Stem Cells Major Manufacturers
Table 6. Genetically Modified Organisms/Crops Major Manufacturers
Table 7. Cell Line Engineering Major Manufacturers
Table 8. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 9. Biotechnology Companies Major Manufacturers
Table 10. Pharmaceutical Companies Major Manufacturers
Table 11. Academic Institutes Major Manufacturers
Table 12. Research and Development Institutes Major Manufacturers
Table 13. CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
Table 14. CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers
Table 15. CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges
Table 16. CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints
Table 17. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 18. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2019-2024) & (US$ Million)
Table 19. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Region (2019-2024)
Table 20. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2025-2030) & (US$ Million)
Table 21. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Region (2025-2030)
Table 22. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Players (US$ Million) & (2019-2024)
Table 23. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Players (2019-2024)
Table 24. Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Ranking, 2022 VS 2023 VS 2024
Table 25. Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Headquarters & Area Served
Table 26. Global CRISPR and CRISPR-Associated (Cas) Genes Players, Product Type & Application
Table 27. Global CRISPR and CRISPR-Associated (Cas) Genes Players Commercialization Time
Table 28. Global Players Market Concentration Ratio (CR5 and HHI)
Table 29. Global CRISPR and CRISPR-Associated (Cas) Genes by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 30. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024) & (US$ Million)
Table 32. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030) & (US$ Million)
Table 33. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 34. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 35. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024) & (US$ Million)
Table 37. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030) & (US$ Million)
Table 38. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 39. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 40. Thermo Fisher Scientific Company Information
Table 41. Thermo Fisher Scientific Business Overview
Table 42. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 43. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 44. Thermo Fisher Scientific Recent Development
Table 45. Editas Medicine Company Information
Table 46. Editas Medicine Business Overview
Table 47. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 48. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 49. Editas Medicine Recent Development
Table 50. Caribou Biosciences Company Information
Table 51. Caribou Biosciences Business Overview
Table 52. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 53. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 54. Caribou Biosciences Recent Development
Table 55. CRISPR therapeutics Company Information
Table 56. CRISPR therapeutics Business Overview
Table 57. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 58. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 59. CRISPR therapeutics Recent Development
Table 60. Intellia therapeutics, Inc. Company Information
Table 61. Intellia therapeutics, Inc. Business Overview
Table 62. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 63. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 64. Intellia therapeutics, Inc. Recent Development
Table 65. Cellectis Company Information
Table 66. Cellectis Business Overview
Table 67. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 68. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 69. Cellectis Recent Development
Table 70. Horizon Discovery Plc Company Information
Table 71. Horizon Discovery Plc Business Overview
Table 72. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 73. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 74. Horizon Discovery Plc Recent Development
Table 75. Sigma Aldrich Company Information
Table 76. Sigma Aldrich Business Overview
Table 77. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 78. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 79. Sigma Aldrich Recent Development
Table 80. Precision Biosciences Company Information
Table 81. Precision Biosciences Business Overview
Table 82. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 83. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 84. Precision Biosciences Recent Development
Table 85. Genscript Company Information
Table 86. Genscript Business Overview
Table 87. Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 88. Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 89. Genscript Recent Development
Table 90. Sangamo Biosciences Inc. Company Information
Table 91. Sangamo Biosciences Inc. Business Overview
Table 92. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 94. Sangamo Biosciences Inc. Recent Development
Table 95. Lonza Group Limited Company Information
Table 96. Lonza Group Limited Business Overview
Table 97. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 99. Lonza Group Limited Recent Development
Table 100. Integrated DNA Technologies Company Information
Table 101. Integrated DNA Technologies Business Overview
Table 102. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 104. Integrated DNA Technologies Recent Development
Table 105. New England Biolabs Company Information
Table 106. New England Biolabs Business Overview
Table 107. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 109. New England Biolabs Recent Development
Table 110. Origene Technologies Company Information
Table 111. Origene Technologies Business Overview
Table 112. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 114. Origene Technologies Recent Development
Table 115. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024) & (US$ Million)
Table 116. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024) & (US$ Million)
Table 117. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 118. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024) & (US$ Million)
Table 119. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030) & (US$ Million)
Table 120. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024) & (US$ Million)
Table 121. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024) & (US$ Million)
Table 122. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 123. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024) & (US$ Million)
Table 124. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030) & (US$ Million)
Table 125. China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024) & (US$ Million)
Table 126. China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024) & (US$ Million)
Table 127. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024) & (US$ Million)
Table 128. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024) & (US$ Million)
Table 129. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 130. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024) & (US$ Million)
Table 131. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030) & (US$ Million)
Table 132. MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024) & (US$ Million)
Table 133. MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024) & (US$ Million)
Table 134. MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 135. MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024) & (US$ Million)
Table 136. MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030) & (US$ Million)
Table 137. Research Programs/Design for This Report
Table 138. Authors List of This Report
Table 139. Secondary Sources
Table 140. Primary Sources
Table 1. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Genome Editing Major Manufacturers
Table 2. Genetic engineering Major Manufacturers
Table 3. gRNA Database/Gene Librar Major Manufacturers
Table 4. CRISPR Plasmid Major Manufacturers
Table 5. Human Stem Cells Major Manufacturers
Table 6. Genetically Modified Organisms/Crops Major Manufacturers
Table 7. Cell Line Engineering Major Manufacturers
Table 8. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 9. Biotechnology Companies Major Manufacturers
Table 10. Pharmaceutical Companies Major Manufacturers
Table 11. Academic Institutes Major Manufacturers
Table 12. Research and Development Institutes Major Manufacturers
Table 13. CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
Table 14. CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers
Table 15. CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges
Table 16. CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints
Table 17. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 18. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2019-2024) & (US$ Million)
Table 19. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Region (2019-2024)
Table 20. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2025-2030) & (US$ Million)
Table 21. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Region (2025-2030)
Table 22. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Players (US$ Million) & (2019-2024)
Table 23. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Players (2019-2024)
Table 24. Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Ranking, 2022 VS 2023 VS 2024
Table 25. Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Headquarters & Area Served
Table 26. Global CRISPR and CRISPR-Associated (Cas) Genes Players, Product Type & Application
Table 27. Global CRISPR and CRISPR-Associated (Cas) Genes Players Commercialization Time
Table 28. Global Players Market Concentration Ratio (CR5 and HHI)
Table 29. Global CRISPR and CRISPR-Associated (Cas) Genes by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 30. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024) & (US$ Million)
Table 32. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030) & (US$ Million)
Table 33. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 34. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 35. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024) & (US$ Million)
Table 37. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030) & (US$ Million)
Table 38. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 39. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 40. Thermo Fisher Scientific Company Information
Table 41. Thermo Fisher Scientific Business Overview
Table 42. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 43. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 44. Thermo Fisher Scientific Recent Development
Table 45. Editas Medicine Company Information
Table 46. Editas Medicine Business Overview
Table 47. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 48. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 49. Editas Medicine Recent Development
Table 50. Caribou Biosciences Company Information
Table 51. Caribou Biosciences Business Overview
Table 52. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 53. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 54. Caribou Biosciences Recent Development
Table 55. CRISPR therapeutics Company Information
Table 56. CRISPR therapeutics Business Overview
Table 57. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 58. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 59. CRISPR therapeutics Recent Development
Table 60. Intellia therapeutics, Inc. Company Information
Table 61. Intellia therapeutics, Inc. Business Overview
Table 62. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 63. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 64. Intellia therapeutics, Inc. Recent Development
Table 65. Cellectis Company Information
Table 66. Cellectis Business Overview
Table 67. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 68. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 69. Cellectis Recent Development
Table 70. Horizon Discovery Plc Company Information
Table 71. Horizon Discovery Plc Business Overview
Table 72. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 73. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 74. Horizon Discovery Plc Recent Development
Table 75. Sigma Aldrich Company Information
Table 76. Sigma Aldrich Business Overview
Table 77. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 78. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 79. Sigma Aldrich Recent Development
Table 80. Precision Biosciences Company Information
Table 81. Precision Biosciences Business Overview
Table 82. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 83. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 84. Precision Biosciences Recent Development
Table 85. Genscript Company Information
Table 86. Genscript Business Overview
Table 87. Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 88. Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 89. Genscript Recent Development
Table 90. Sangamo Biosciences Inc. Company Information
Table 91. Sangamo Biosciences Inc. Business Overview
Table 92. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 94. Sangamo Biosciences Inc. Recent Development
Table 95. Lonza Group Limited Company Information
Table 96. Lonza Group Limited Business Overview
Table 97. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 99. Lonza Group Limited Recent Development
Table 100. Integrated DNA Technologies Company Information
Table 101. Integrated DNA Technologies Business Overview
Table 102. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 104. Integrated DNA Technologies Recent Development
Table 105. New England Biolabs Company Information
Table 106. New England Biolabs Business Overview
Table 107. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 109. New England Biolabs Recent Development
Table 110. Origene Technologies Company Information
Table 111. Origene Technologies Business Overview
Table 112. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 114. Origene Technologies Recent Development
Table 115. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024) & (US$ Million)
Table 116. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024) & (US$ Million)
Table 117. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 118. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024) & (US$ Million)
Table 119. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030) & (US$ Million)
Table 120. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024) & (US$ Million)
Table 121. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024) & (US$ Million)
Table 122. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 123. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024) & (US$ Million)
Table 124. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030) & (US$ Million)
Table 125. China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024) & (US$ Million)
Table 126. China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024) & (US$ Million)
Table 127. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024) & (US$ Million)
Table 128. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024) & (US$ Million)
Table 129. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 130. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024) & (US$ Million)
Table 131. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030) & (US$ Million)
Table 132. MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019-2024) & (US$ Million)
Table 133. MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019-2024) & (US$ Million)
Table 134. MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 135. MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2019-2024) & (US$ Million)
Table 136. MEALA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2025-2030) & (US$ Million)
Table 137. Research Programs/Design for This Report
Table 138. Authors List of This Report
Table 139. Secondary Sources
Table 140. Primary Sources
LIST OF FIGURES
Figure 1. CRISPR and CRISPR-Associated (Cas) Genes Product Picture
Figure 2. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Share 2019 VS 2023 VS 2030
Figure 4. Genome Editing Picture
Figure 5. Genetic engineering Picture
Figure 6. gRNA Database/Gene Librar Picture
Figure 7. CRISPR Plasmid Picture
Figure 8. Human Stem Cells Picture
Figure 9. Genetically Modified Organisms/Crops Picture
Figure 10. Cell Line Engineering Picture
Figure 11. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Share 2019 VS 2023 VS 2030
Figure 13. Biotechnology Companies Picture
Figure 14. Pharmaceutical Companies Picture
Figure 15. Academic Institutes Picture
Figure 16. Research and Development Institutes Picture
Figure 17. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (US$ Million) & (2019-2030)
Figure 18. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Region: 2019 VS 2023 VS 2030
Figure 20. Global CRISPR and CRISPR-Associated (Cas) Genes Players Revenue Share Top 10 and Top 5 in 2023
Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 22. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 23. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share 2019 VS 2023 VS 2030
Figure 24. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2019-2030)
Figure 25. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 26. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 27. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2019-2030)
Figure 28. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 29. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030) & (US$ Million)
Figure 30. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
Figure 31. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030) & (US$ Million)
Figure 32. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
Figure 33. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Country (2019-2030)
Figure 34. United States CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 35. Canada CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 36. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 37. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030) & (US$ Million)
Figure 38. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
Figure 39. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030) & (US$ Million)
Figure 40. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
Figure 41. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Country (2019-2030)
Figure 42. Germany CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. France CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. U.K. CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 45. Italy CRISPR and
Figure 1. CRISPR and CRISPR-Associated (Cas) Genes Product Picture
Figure 2. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Share 2019 VS 2023 VS 2030
Figure 4. Genome Editing Picture
Figure 5. Genetic engineering Picture
Figure 6. gRNA Database/Gene Librar Picture
Figure 7. CRISPR Plasmid Picture
Figure 8. Human Stem Cells Picture
Figure 9. Genetically Modified Organisms/Crops Picture
Figure 10. Cell Line Engineering Picture
Figure 11. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Share 2019 VS 2023 VS 2030
Figure 13. Biotechnology Companies Picture
Figure 14. Pharmaceutical Companies Picture
Figure 15. Academic Institutes Picture
Figure 16. Research and Development Institutes Picture
Figure 17. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (US$ Million) & (2019-2030)
Figure 18. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Region: 2019 VS 2023 VS 2030
Figure 20. Global CRISPR and CRISPR-Associated (Cas) Genes Players Revenue Share Top 10 and Top 5 in 2023
Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 22. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 23. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share 2019 VS 2023 VS 2030
Figure 24. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2019-2030)
Figure 25. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 26. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 27. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2019-2030)
Figure 28. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 29. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030) & (US$ Million)
Figure 30. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
Figure 31. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030) & (US$ Million)
Figure 32. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
Figure 33. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Country (2019-2030)
Figure 34. United States CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 35. Canada CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 36. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 37. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2025-2030) & (US$ Million)
Figure 38. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2019-2030)
Figure 39. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2025-2030) & (US$ Million)
Figure 40. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2019-2030)
Figure 41. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Country (2019-2030)
Figure 42. Germany CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. France CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. U.K. CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 45. Italy CRISPR and
